What’s in the pipeline? Drugs in development for autism spectrum disorder
Sung, Min; Chin, Chee Hon; Lim, Choon Guan; Hwee Sen Liew, Alvin; Lim, Chau Sian; Kashala, Espérance; Weng, Shih-Jen
Peer reviewed, Journal article
Published version
Permanent lenke
https://hdl.handle.net/1956/8935Utgivelsesdato
2014-02-20Metadata
Vis full innførselSamlinger
Originalversjon
https://doi.org/10.2147/ndt.s39516Sammendrag
Autism Spectrum Disorder (ASD) is a complex neurodevelopmental disorder with both core symptoms and associated symptoms (eg, irritability, aggression, and comorbidities) that affect both the individual and the family/systems around them. There have been recent advances in the understanding of the underlying pathophysiology of ASD pertaining to genetics, epigenetics, neurological, hormonal, and environmental factors that contribute to the difficulties found in individuals with ASD. With this improved understanding, there has been a shift in the application of psychopharmacology in ASD and its related disorders. A literature review was conducted to examine research published in the last 5 years between different classes of psychotropic medications and ASD. The broad scope of the existing literature for the use of conventional medications is summarized and novel medications are discussed.